Magnus Persson - 20 Dec 2023 Form 4 Insider Report for Avalo Therapeutics, Inc. (AVTX)

Role
Director
Signature
/s/ Christopher Sullivan, by Power of Attorney
Issuer symbol
AVTX
Transactions as of
20 Dec 2023
Transactions value $
$0
Form type
4
Filing time
21 Dec 2023, 16:05:31 UTC
Previous filing
05 Jul 2023
SEC
View on sec.gov

Derivative Securities (e.g., puts, calls, warrants, options, convertible securities)

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Underlying Class Amount Exercise Price Ownership Footnotes
transaction AVTX Stock Option (Right to Buy) Award $0 +3,334 $0 3,334 20 Dec 2023 Common Stock 3,334 $0.043 Direct F1
* An asterisk sign (*) next to the price indicates that the price is likely invalid.

Explanation of Responses:

Id Content
F1 The stock option will vest in full on December 20, 2024, subject to the Reporting Person's continued service on such vesting date.